Arcturus Shares Jump 32.6% on Q2 Filings, ARK Stake and Phase 2 LUNAR-OTC Data

Introduction

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial messenger RNA (mRNA) medicines company headquartered in San Diego, California. Founded in 2013, the company develops therapies for liver and respiratory rare diseases and infectious disease vaccines using its proprietary LUNAR® lipid-mediated delivery and STARR® self-amplifying mRNA technologies. On August 12, 2025, ARCT closed at USD 15.10 on the NASDAQ, reflecting a 32.57% increase with 612,129 shares traded.

Corporate Structure

Arcturus employs between 51 and 200 professionals working across research, clinical development, manufacturing, and corporate functions. Its leadership team includes founders Joseph Payne and Pad Chivukula, supported by a board of directors appointed under a settlement agreement made in May 2018. The company’s operations are organized into:

• mRNA therapeutics for rare diseases (e.g., ornithine transcarbamylase deficiency, cystic fibrosis)
• Partnered and in-house vaccine programs (COVID-19, seasonal, and pandemic influenza)
• Drug substance and drug product manufacturing capabilities

mRNA therapeutics by Michał Parzuchowski

Recent Developments and News

• Form 10-Q Filing (August 11, 2025): Arcturus submitted its quarterly report for the period ended June 30, 2025. While specific figures have not been disclosed, the report typically includes revenue trends, net loss, R&D expenditures, and liquidity positions.
• Form 8-K Filing (August 11, 2025): The company disclosed items related to its second-quarter operations and material agreements; specifics will be detailed in the SEC filing.
• Schedule 13G/A Amendment (July 30, 2025): ARK Investment Management LLC and Catherine D. Wood reported beneficial ownership of 1,715,040 shares, constituting 6.32% of Arcturus’s outstanding common stock as of June 30, 2025.
• Phase 2 Data Update (July 2025): Arcturus provided interim multiple-dose data for ARCT-810 (LUNAR-OTC) in patients with ornithine transcarbamylase deficiency, indicating restoration of urea-cycle function in preclinical models.
• BIO International Convention Premiere (June 3, 2025): As part of the “The Next Frontier” series, the company premiered “The Next Generation of mRNA Therapeutics,” featuring discussions on cystic fibrosis and an overview of the LUNAR-CF program.
• World RNA Day (March 7, 2025): Arcturus highlighted advancements in self-amplifying mRNA vaccines and therapies for rare diseases.

Financial and Strategic Analysis

Arcturus’s August 11, 2025, Form 10-Q filing is expected to clarify key metrics such as R&D spending, anticipated to reflect the progression of LUNAR-OTC towards an end-of-Phase 2 meeting scheduled for H1 2026, alongside investments in manufacturing for KOSTAIVE® (self-amplifying COVID-19 vaccine) and seasonal influenza candidates. Risk factors may include regulatory approval timelines, clinical trial outcomes, and financial sustainability typical of biotechnology firms. Strategically, the company maintains:

• Collaborations with CSL Seqirus for global mRNA vaccine development and BARDA for pandemic influenza preparedness
• Intellectual property protections covering over 500 patents and applications globally
• Manufacturing ventures such as the ARCALIS joint venture in Japan

The Schedule 13G/A filing suggests institutional interest, while liquidity may depend on potential equity or partnership funding to support ongoing clinical trials.

Market Position and Industry Context

In the mRNA sector, Arcturus operates alongside companies such as Moderna and BioNTech but differentiates itself with self-amplifying mRNA technology and a focus on rare metabolic and respiratory disorders. Its approved product, KOSTAIVE® (authorized in Japan in 2023 and the European Union in 2025), addresses specific needs within niche markets, including ornithine transcarbamylase deficiency (approximately 10,000 global cases) and cystic fibrosis (over 85,000 patients worldwide).

TL;DR

As of August 11, 2025, Arcturus filed its Q2 2025 Form 10-Q and Form 8-K, outlining quarterly performance and operational updates for the period ended June 30, 2025. A Schedule 13G/A from July 30, 2025, indicates that ARK Investment Management LLC holds 6.32% of shares. Phase 2 data for ARCT-810 (LUNAR-OTC) supports a planned end-of-Phase 2 meeting in H1 2026. The company's pipeline includes self-amplifying mRNA vaccines and therapies for rare diseases and is supported by collaborations with CSL Seqirus and BARDA.